Novel targeted therapies in adrenocortical carcinoma.

摘要: Purpose of review Adrenocortical carcinoma is a rare cancer, but one that carries poor prognosis due to its aggressive nature and unresponsiveness conventional chemotherapeutic strategies. Over the past 12 years, there has been renewed interest in developing new therapies for this including identifying key signaling nodes responsible cell proliferation. Recent findings Clinical trials tyrosine kinase inhibitors as monotherapy have generally disappointing, although identification exceptional responders may lead targeted produce responses subsets patients. Agents Wnt pathway, known player adrenal carcinogenesis, developed, they not yet used specifically cancer. There current excitement about acetyl-coA cholesterol acetyl transferase 1, an enzyme required intracellular handling, are still underway. Tools target other proteins such Steroidogenic Factor 1 mechanistic rapamycin developed moving towards clinical application. Summary Progress being made fight against adrenocortical with therapeutic targets means by which attack them. Continued improvement patients cancer expected research continues.